MTOR and hepatocellular carcinoma: The phosphatidylinositol 3-kinase/mammalian target of rapamycin (PI3K/mTOR) pathway is aberrantly activated in variable types of cancers [10, 11], including in 30-50% of HCC cases [12, 13].